Influence of TASP-V, a novel neuropeptide Y (NPY) Y2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans

Détails

ID Serval
serval:BIB_31BFE5E1EE8F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Influence of TASP-V, a novel neuropeptide Y (NPY) Y2 agonist, on nasal and bronchial responses evoked by histamine in anaesthetized pigs and in humans
Périodique
British Journal of Pharmacology
Auteur(s)
Malis  D. D., Grouzmann  E., Morel  D. R., Mutter  M., Lacroix  J. S.
ISSN
0007-1188 (Print)
Statut éditorial
Publié
Date de publication
02/1999
Volume
126
Numéro
4
Pages
989-96
Notes
Clinical Trial
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Feb
Résumé
1. In nine anaesthetized pigs we have studied the influence of intranasal or intrabronchial pretreatment with TASP-V, a neuropeptide Y (NPY) Y2 agonist formed by the attachment of NPY 21-36 to a template-assembled synthetic peptide (TASP), on the functional responses to subsequent intranasal or intrabronchial histamine challenge. 2. In a parallel study, subjective and objective nasal airway resistance (NAR) increase following intranasal histamine challenge was evaluated in 11 healthy volunteers after TASP-V or placebo pretreatment. 3. In pigs, increase in sphenopalatine blood flow induced by histamine dihydrochloride nasal spray (0.25 mg kg(-1) in 3 ml of saline) was significantly reduced by 65% (P<0.05) following intranasal pretreatment with 10 microg kg(-1) of TASP-V. Bronchoconstriction induced by histamine dihydrochloride nebulization (0.5 mg kg(-1) in 3 ml of saline) was significantly attenuated by 25 and 55% following aerosolized pretreatment with TASP-V analogue at 10 and 20 microg kg(-1), respectively. 4. In healthy volunteers, objective increase in NAR and reduction in nasal minimal cross section area (MCSA) induced by intranasal spray of histamine dihydrochloride (15 microg kg(-1) in 200 microl of saline) were significantly attenuated by 50% following local pretreatment with 1.275 microg kg(-1) of TASP-V when compared with saline. 5. It is concluded that intranasal or intrabronchial pretreatment with TASP-V reduced nasal obstruction and bronchoconstriction evoked by histamine challenge in the pig. In healthy human volunteers, this agent attenuated NAR increase and MCSA reduction induced by intranasal application of histamine.
Mots-clé
Adult Anesthesia Animals Bronchi/*drug effects/physiology Bronchoconstriction/drug effects Calcitonin Gene-Related Peptide/physiology Female Hemodynamic Processes/drug effects Histamine/*pharmacology Humans Male Middle Aged Nasal Mucosa/*drug effects/physiology Neuropeptide Y/*pharmacology Peptide Fragments/*pharmacology Receptors, Neuropeptide Y/*agonists Substance P/physiology Swine
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 11:55
Dernière modification de la notice
20/08/2019 14:17
Données d'usage